Posttranscriptional control of NLRP3 inflammasome activation in colonic macrophages

Mucosal Immunology

Volumn 9, Issue 4, 2016, Pages 850-858

  Filardy, A A ^a   He, J ^a   Bennink, J ^a   Yewdell, J ^a   Kelsall, B L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLAMMASOME; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; CRYOPYRIN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL POPULATION; COLONIC MACROPHAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL COLITIS; FEMALE; GENE CONTROL; GENETIC TRANSCRIPTION; IN VIVO STUDY; MACROPHAGE; MOUSE; NLRP3 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CULTURE; COLITIS; COLON; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; TRANSPLANTATION; TUMOR MICROENVIRONMENT; UBIQUITINATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CELLULAR MICROENVIRONMENT; COLITIS; COLON; INFLAMMASOMES; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, INTERLEUKIN-10; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINATION;

EID: 84975810743     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2015.109     Document Type: Article

References (42)

1. Bain, C.C. et al. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 6, 498-510 (2013).
2. Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B.L. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med. 209, 139-155 (2012).
3. Tamoutounour, S. et al. CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. Eur. J. Immunol. 42, 3150-3166 (2012).
4. Zigmond, E. et al. Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37, 1076-1090 (2012).
5. Shouval, D.S. et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 40, 706-719 (2014).
6. Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40, 720-733 (2014).
7. Lavin, Y. et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 159, 1312-1326 (2014).
8. Franchi, L., Munoz-Planillo, R. & Nunez, G. Sensing and reacting to microbes through the inflammasomes. Nat. Immunol. 13, 325-332 (2012).
9. Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl. Acad. Sci. USA 107, 21635-21640 (2010).
10. Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192-1199 (2010).
11. Monteleone, G. et al. Bioactive IL-18 expression is up-regulated in Crohns disease. J. Immunol. 163, 143-147 (1999).
12. Casini-Raggi, V. et al. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154, 2434-2440 (1995).
13. Ligumsky, M., Simon, P.L., Karmeli, F. Rachmilewitz, D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 31, 686-689 (1990).
14. Pizarro, T.T. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohns disease: expression and localization in intestinal mucosal cells. J Immunol 162, 6829-6835 (1999).
15. Denning, T.L., Wang, Y.C., Patel, S.R., Williams, I.R. & Pulendran, B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing Tcell responses. Nat. Immunol. 8, 1086-1094 (2007).
16. Smythies, L.E. et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66-75 (2005).
17. Bauernfeind, F.G. et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009).
18. Kontoyiannis, D. et al. Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J. 20, 3760-3770 (2001).
19. Smallie, T. et al. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J. Exp. Med. 207, 2081-2088 (2010).
20. Iwasaki, H. et al. The IkappaB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat. Immunol. 12, 1167-1175 (2011).
21. Masuda, K. et al. Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc. Natl. Acad. Sci. USA 110, 9409-9414 (2013).
22. Guarda, G. et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213-223 (2011).
23. Powrie, F., Leach, M.W., Mauze, S., Caddle, L.B. & Coffman, R.L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5, 1461-1471 (1993).
24. Carpenter, S., Ricci, E.P., Mercier, B.C., Moore, M.J. & Fitzgerald, K.A. Post-Transcriptional regulation of gene expression in innate immunity. Nat. Rev. Immunol. 14, 361-376 (2014).
25. Ainscough, J.S. et al. Dendritic cell IL-1alpha and IL-1beta are polyubiquitinated and degraded by the proteasome. J. Biol. Chem. 289, 35582-35592 (2014).
26. Juliana, C. et al. Non-Transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287, 36617-36622 (2012).
27. Py, B.F., Kim, M.S., Vakifahmetoglu-Norberg, H. & Yuan, J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49, 331-338 (2013).
28. Duong, B.H. et al. A20 restricts ubiquitination of pro-interleukin-1beta protein complexes and suppresses NLRP3 inflammasome activity. Immunity 42, 55-67 (2015).
29. Elliott, P.J., Zollner, T.M. & Boehncke, W.H. Proteasome inhibition: A new anti-inflammatory strategy. J. Mol. Med. (Berl) 81, 235-245 (2003).
30. Kisselev, A.F. & Goldberg, A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739-758 (2001).
31. Lee, D.H. & Goldberg, A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell. Biol. 8, 397-403 (1998).
32. Moore, B.S., Eustaquio, A.S. & McGlinchey, R.P. Advances in and applications of proteasome inhibitors. Curr. Opin. Chem. Biol. 12, 434-440 (2008).
33. Glocker, E.O., Kotlarz, D., Klein, C., Shah, N. & Grimbacher, B. IL-10 and IL-10 receptor defects in humans. Ann NY Acad. Sci. 1246, 102-107 (2011).
34. Murugan, D. et al. Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. J. Clin. Immunol. 34, 331-339 (2014).
35. Franchi, L. et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449-456 (2012).
36. Kunisawa, J. et al. Microbe-dependent CD11b+ IgA+ plasma cells mediate robust early-phase intestinal IgA responses in mice. Nat. Commun. 4, 1772 (2013).
37. Chaudhry, A. et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34, 566-578 (2011).
38. Murai, M. et al. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 10, 1178-1184 (2009).
39. Huber, S. et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34, 554-565 (2011).
40. Glocker, E.O. et al. Inflammatory bowel disease andmutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033-2045 (2009).
41. Bauernfeind, F. et al. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 189, 4175-4181 (2012).
42. von Moltke, J. et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490, 107-111 (2012).